[猪去氧胆酸通过肠-肝轴治疗MASLD机制的研究进展]
[Research progress on the mechanism of hyodeoxycholic acid in the treatment of MASLD through the gut-liver axis].
摘要(中文译文)
代谢功能障碍相关脂肪性肝病（MASLD）是一种影响全球超过30%成年人口的代谢性肝病，其患病率和死亡率持续上升。猪去氧胆酸（HDCA）是一种天然次级亲水性胆汁酸，也是中药猪胆粉的主要活性成分，多项研究已证实其可改善MASLD及其他肝脏代谢紊乱，其疗效可能优于二甲双胍。本文系统探讨了HDCA通过与法尼醇X受体（FXR）、Takeda G蛋白偶联受体5（TGR5）、肝X受体（LXR）等胆汁酸受体以及肠道菌群的相互作用，在肠-肝轴和外周组织中对糖代谢、脂质代谢及炎症反应的多方面调控机制。本文旨在为MASLD及代谢功能障碍相关脂肪性肝炎（MASH）的安全治疗提供理论基础和治疗靶点。
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a metabolic liver disorder affecting over 30% of the global adult population, with its prevalence and mortality rates continuing to rise. Hyodeoxycholic acid (HDCA), a natural secondary hydrophilic bile acid and the primary active component of traditional Chinese medicine gallbladder powder, has been demonstrated by multiple studies to ameliorate MASLD and other hepatic metabolic disorders, potentially exhibiting superior efficacy to metformin. This review systematically discusses the multifaceted regulatory mechanisms of HDCA on glucose metabolism, lipid metabolism, and inflammatory responses in the gut-liver axis and peripheral tissues through its interactions with bile acid receptors including farnesoid X receptor (FXR), Takeda G protein-coupled receptor-5 (TGR5), liver X receptor (LXR) and with gut microbiota. The paper aims to provide theoretical foundations and therapeutic targets for the safe treatment of MASLD and metabolic dysfunction-associated steatohepatitis (MASH).
如何引用
AMA
Rui Li, Wen-Qing Shen. [Research progress on the mechanism of hyodeoxycholic acid in the treatment of MASLD through the gut-liver axis].. Sheng li xue bao : [Acta physiologica Sinica]. 2026; doi:10.13294/j.aps.2026.0051.
APA
Rui Li, Wen-Qing Shen (2026). [Research progress on the mechanism of hyodeoxycholic acid in the treatment of MASLD through the gut-liver axis].. Sheng li xue bao : [Acta physiologica Sinica]. https://doi.org/10.13294/j.aps.2026.0051
GB/T 7714
Rui Li, Wen-Qing Shen. [Research progress on the mechanism of hyodeoxycholic acid in the treatment of MASLD through the gut-liver axis].[J]. Sheng li xue bao : [Acta physiologica Sinica], 2026 doi:10.13294/j.aps.2026.0051.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出